68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial - Top-Institutions - MDSpire

68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial

  • By

  • Patrick Bowden

  • Andrew W. See

  • Kevin So

  • Nathan Lawrentschuk

  • Daniel Moon

  • Declan G. Murphy

  • Ranjit Rao

  • Alan Crosthwaite

  • Dennis King

  • Hodo Haxhimolla

  • Jeremy Grummet

  • Paul Ruljancich

  • Dennis Gyomber

  • Adam Landau

  • Nicholas Campbell

  • Mark Frydenberg

  • Lloyd M. L. Smyth

  • Skye Nolan

  • Stella M. Gwini

  • Dean P. McKenzie

  • June 2, 2021

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Nuclear Medicine
    • Urologic Oncology

  • #2

    University of California, Los Angeles (UCLA) Medical Center
    University of California, Los Angeles (UCLA) Medical Center

    Los Angeles, CA

    Key Differentiators

    • Radiation Oncology
    • Nuclear Medicine
    • Urology

  • #3

    University of Michigan Rogel Cancer Center
    University of Michigan Rogel Cancer Center

    Ann Arbor, MI

    Key Differentiators

    • Radiation Oncology
    • Nuclear Medicine
    • Urologic Oncology

  • #4

    Peter MacCallum Cancer Centre
    Peter MacCallum Cancer Centre

    Melbourne, Victoria

    Key Differentiators

    • Radiation Oncology
    • Nuclear Medicine
    • Urology

Original Source(s)

68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial

  • by Patrick Bowden, Andrew W. See, Kevin So, Nathan Lawrentschuk, Daniel Moon, Declan G. Murphy, Ranjit Rao, Alan Crosthwaite, Dennis King, Hodo Haxhimolla, Jeremy Grummet, Paul Ruljancich, Dennis Gyomber, Adam Landau, Nicholas Campbell, Mark Frydenberg, Lloyd M. L. Smyth, Skye Nolan, Stella M. Gwini, Dean P. McKenzie

  • June 2, 2021

Related Content

Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study

Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy

Optimizing Outcomes: How Multidisciplinary Approaches Improve Prostate Cancer Survival Rates

Prostate cancer management has evolved significantly over the years, propelled by groundbreaking diagnostics and advancements in treatment modalities.

  • by

  • March 18, 2024

  • 4 min